Explore more
News
Novo Nordisk ousts CEO
Digest more
Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...
Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.
Novo Nordisk, the global pharmaceutical leader headquartered in Denmark, has launched a major initiative to combat Thailand’s ...
That’s a bit harsh given Denmark’s strong growth compared with neighboring countries over the past few years has been largely ...
As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have they changed positions in the annual IDEA Pharma Innovation Index, which ...
Investing.com -- S&P Global Ratings has upgraded the Denmark-based pharmaceutical company Novo Nordisk (NYSE: NVO) A/S to ’AA’ from ’AA-’ due to its sustainable strong ongoing growth prospects. The ...
Novo Nordisk (NVO, Financials) shares fell nearly 4% after the company said CEO Lars Fruergaard Jrgensen will step down. A ...
Most major stock indexes across the globe moved upwards on a weekly basis, taking support from the uptick in US equities.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback